MINTEZOL
LOE ApproachingNDAORALSUSPENSION
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINTEZOL is an oral suspension approved in 1967 by Merck & Co. for parasitic infections. The mechanism of action and specific indications are not detailed in available data. This is a legacy small-molecule anthelmintic product with established clinical utility in tropical and neglected disease settings.
LOE Approaching
Legacy product approaching loss of exclusivity with minimal linked job opportunities; team size and investment likely declining as brand prepares for generic entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MINTEZOL offers limited career momentum given zero linked job openings and LOE-approaching status. This role is best suited for professionals seeking stability in legacy product management or transitioning to emerging therapeutic areas within Merck's portfolio.
Brand ManagerField Sales Representative
Worked on MINTEZOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.